来凯医药-B（02105.HK）今日盘中大涨5.24%，股价表现强劲。这一涨幅与公司最新发布的积极研发进展密切相关。
根据公司公告，来凯医药-B在中国开展的LAE102针对肥胖症治疗的I期多剂量递增研究（MAD研究）已启动受试者招募，并且首例受试者已完成首次访视。这标志着公司在开发新型肥胖症治疗药物方面取得重要进展，提振了投资者信心。
LAE102是来凯医药自主研发的针对ActRIIA的单克隆抗体，在临床前模型中显示出增加肌肉并减少脂肪的效果。值得注意的是，LAE102与GLP-1受体激动剂联用可进一步减少脂肪并显著降低GLP-1受体激动剂导致的肌肉流失，使其成为一种潜在的高质量体重控制候选药物。这一进展显示出公司在竞争激烈的肥胖症治疗市场中的创新能力和发展潜力，因此受到市场青睐，推动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.